1. 200MO Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results. (December 2022) Authors: Simonelli, M.; Calvo, E.; Davar, D.; Richards, D.; Gutierrez, M.; Moreno Garcia, V.; Marron, T.; Rottey, S.; Orcurto, A.; Renouf, D.J.; Joerger, M.; Barriga Falcon, S.; Fan, J.; Gibson, E.; Chakraborty, D.; Arora, V.; Melero, I. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗